Fig. 1
Percentage of analyzable tests with correct c.2369C>T p.(Thr790Met) identification for the different technique types. 2/1190 tests were excluded as no method information was available, bringing the total analyzed tests on 1188. The two excluded tests were performed in 2013 during a 1st EQA participation, on cell line material with an allele frequency of 25%, and resulted in one correct result and one technical failure. Correct results are calculated in relation to the total number of analyzable tests (total tests minus technical failures). †The category ‘next-generation sequencing’ includes both commercial and in-house panels. ‡Non-commercial methods include in-house sequencing methods that are non-NGS based. ∥The first and second distribution round of the Lung 2017 scheme are counted as two separate participations (4 months apart). The detailed percentage of correct results, false-negatives, wrong mutations and technical failures is given in Supplemental Table3. Abbreviations: EQA, external quality assessment; NGS, next-generation sequencing